Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...

Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts ...

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing ...

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

The Chinese company also gets commercialisation rights to three already-marketed cancer drugs, as well as co-development rights to 20 candidates in its oncology pipeline, while Amgen gets to ...

Amgen’s discovery pipeline has led the company to broaden its focus from oncology, immunology, and renal disease to include musculoskeletal, cardiovascular, and neurologic conditions.

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...